OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Subscription & copyright page	296
Revumenib: a new era in acute leukemia treatment	283
Advancements in organoid models emulating metastatic niches	270
Engineering growth factor ligands and receptors for therapeutic innovation	254
FBXW10: a male-biased E3 ligase in liver cancer	234
Pseudomyxoma peritonei and the microbiome: Emerging observations and unanswered questions	234
An immunological panacea for cancer-related cachexia	223
Platelets: tailoring metastasis treatment	213
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	200
Spliced to kill: RNA mis-splicing derived cancer neoantigens	197
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	176
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	174
Tumor-resident microbes: the new kids on the microenvironment block	172
Navigating life as an early career researcher	162
Subscription & copyright page	157
Advisory Board and Contents	156
Leveraging circulating microbial DNA for early cancer detection	149
Onco-condensates: formation, multi-component organization, and biological functions	127
Under pressure: clonal hematopoiesis in patients receiving cancer therapy	126
Accessing the vasculature in cancer: revising an old hallmark	121
Engine shutdown: migrastatic strategies and prevention of metastases	118
Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness	115
The evolving landscape of brain metastasis: volume II	114
Regulation of metastatic organotropism	111
Subscription & copyright page	110

GOT2 consider the tumor microenvironment	109
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	108
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	106
Oncogenic competence: balancing mutations, cellular state, and microenvironment	99
FGFR rearrangements: oncogenic drivers and therapeutic targets	87
Benefits and opportunities of the transgenic Oncopig cancer model	85
Mitochondrial transfer reveals an organellar layer of cancer ecology	84
From prediction to precision: how immunopeptidomics advances neoantigen discovery	82
Recent developments in myeloid immune modulation in cancer therapy	82
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	81
Neural hijacking in cancer metabolism: from nutrients to organelles	80
Chromatin as an old and new anticancer target	74
Diet, nutrient supply, and tumor immune responses	74
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	72
Crosstalk of T cells within the ovarian cancer microenvironment	71
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	70
Gut microbiota – a double-edged sword in cancer immunotherapy	70
Cell death, therapeutics, and the immune response in cancer	70
Subscription & copyright page	69
Advisory Board and Contents	69
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk	69
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	69
Palmitate paves the way to lung metastasis	65
Horizontal mitochondrial transfer and the tug-of-war between cancer cells and immune cells	64
Organellar pH as an emerging vulnerability to exploit in cancer	63
Planning for cancer: building accessible and high-quality survivorship care for all	63
Neural checkpoint therapy in lung cancer	62
Genetic immune escape in cancer: timing and implications for treatment	62
Scaling data toward pan-cancer foundation models	60
Clinical and translational relevance of intratumor heterogeneity	60
Inflammation: the incubator of the tumor microenvironment	58
The emerging field of oncolytic virus-based cancer immunotherapy	56
Subscription & copyright page	56
Advisory Board and Contents	54
Advisory Board and Contents	53
Advisory Board and Contents	53
Molecular and clinical insights into early-onset endometrial cancer	52
Advisory Board and Contents	52
Emerging mechanisms of telomerase reactivation in cancer	52
Advancing cancer precision surgery with the tumor coagulome	52
Gut microbial metabolites for potentiating cancer therapy	51
Updating cancer research with patient-focused networks	51
Microbiome: a driver of pancreatic inflammation and tumorigenesis	51
RHOA takes the RHOad less traveled to cancer	50
Stress granules and hormetic adaptation of cancer	49
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	49
Circulating cell-free DNA-based multi-cancer early detection	49
TRANSCLINSCI_COL	49
Prospects for understanding and exploiting the consequences of hyperactivation lethality	49
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	48

B7-H3: a robust target for immunotherapy in prostate cancer	48
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	48
A novel mechanism of autophagy-dependent immunosuppression in cancer?	48
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	47
Advisory Board and Contents	46
Advisory Board and Contents	46
A macrophage-neutrophil program drives mammary carcinogenesis	45
Subscription & copyright page	44
Advisory Board and Contents	43
Mechanistic cancer prevention comes of age	43
Advisory Board and Contents	43
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	42
Subscription & copyright page	42
Leveraging space innovations for cancer breakthroughs on Earth	40
RNA vaccines for cancer: revolutionizing immunization strategies	40
Beyond safety: suicide systems in cell-based cancer therapies	40
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	39
Targeting TIM-3 to halt lung precancer progression	38
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	38
Branched chain amino acids and their aberrant metabolism in cancer	38
The promise of TIL therapy for glioblastoma	38
Time-of-day dependency of adoptive cell therapies	37
CAR T cell persistence in cancer	37
Neoantigen-directed therapeutics in the clinic: where are we?	36
Ferroptosis vulnerability in FLT3-mutant leukemia	35
Functional heterogeneity of fibroblasts in primary tumors and metastases	35
Advisory Board and Contents	35
Subscription & copyright page	35
Space in cancer biology: its role and implications	34
Advisory Board and Contents	34
Advisory Board and Contents	34
Neural circuits in lung adenocarcinoma modulate immunosurveillance	33
ApCAFs: spatial niches and therapeutic insights across cancers	32
Advisory Board and Contents	32
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	32
Clonal evolution and hierarchy in myeloid malignancies	32
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	31
Dissecting histological transformation	31
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Engineered bacterial therapeutics for detecting and treating CRC	30
Addressing the genetic/nongenetic duality in cancer with systems biology	30
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	29
Subscription & copyright page	29
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	28
Genitourinary cancer neoadjuvant therapies: current and future approaches	28
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
Lifileucel: the first cellular therapy approved for solid tumours	27
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
Next-generation cancer vaccines and emerging immunotherapy combinations	26
Immunomodulation by endothelial cells: prospects for cancer therapy	26
Successfully targeting the cancer system with metronomics for medulloblastoma	26
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	26
Mesothelioma: a systemic therapy clinical trials snapshot	26
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	26
NETscape or NEThance: tailoring anti-cancer therapy	26
Subscription & copyright page	26
Advisory Board and Contents	25
Subscription & copyright page	25
Embracing diversity: macrophage complexity in cancer	24
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	24
Deciphering the roles of ABCB5 in normal and cancer cells	23
How DNA methylation predicts response to cancer therapies	22
The extracellular matrix in cancer: from understanding to targeting	22
Persisting cancer cells are different from bacterial persisters	22
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	21
Enhancing dendritic cells by inhibiting BCL2	21
Subscription & copyright page	21
How cancer cells make and respond to interferon-I	21
Fueling the revolution: RIBOTACs manipulating RNA decay	21
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	21
Emerging and extensive clonal evolution in the pancreas	21
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	21
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	21
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	21
Future perspectives on engineered T cells for cancer	21